Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia

Michael J. Clemente, Marcin W. Wlodarski, Hideki Makishima, Aaron D. Viny, Isabell Bretschneider, Mohammad Shaik, Nelli Bejanyan, Alan E. Lichtin, Eric D. Hsi, Ronald L. Paquette, Thomas P. Loughran, Jr, Jaroslaw P. Maciejewski

Blood (2011) 118 (16): 4384–4393.

https://doi.org/10.1182/blood-2011-02-338517

Published: 2011

Includes: Supplemental data

Journal Articles

Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia.

Michael J. Clemente, Marcin W. Wlodarski, M.D., Aaron D. Viny, Mohammed Shaik, Nelli Bejanyan, Sanjay R. Mohan, Hideki Makishima, Alan E. Lichtin, Eric D. Hsi, Ronald L. Paquette, Thomas P. Loughran, Jr, Jaroslaw P. Maciejewski

Blood (2010) 116 (21): 1171.

https://doi.org/10.1182/blood.V116.21.1171.1171

Published: 2010

Journal Articles

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Ronald L. Paquette, MD, Neil P. Shah, MD, PhD, Charles L. Sawyers, MD, Giovanni Martinelli, MD, Nicoll John, Meenal Chalukya, Maurizio Rocchetti, PhD, Carina Fiocchi, MD, Sylvia Comis, MD, Laura Capolongo, MD, Bernard Laffranchi, MD

Blood (2007) 110 (11): 1030.

https://doi.org/10.1182/blood.V110.11.1030.1030

Published: 2007

Journal Articles

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark L. Heaney, Stephen D. Nimer, Ronald L. Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nick Holford, Peter T. Curtin, Brian J. Druker, Michael C. Heinrich

Blood (2006) 108 (12): 3674–3681.

https://doi.org/10.1182/blood-2006-02-005702

Published: 2006

Journal Articles

Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors.

Neil P. Shah, MD, PhD, Brian Skaggs, PhD, Susan Branford, BS, Timothy P. Hughes, MD, John M. Nicoll, BS, Ronald L. Paquette, MD, Charles L. Sawyers, MD

Blood (2006) 108 (11): 751.

https://doi.org/10.1182/blood.V108.11.751.751

Published: 2006

Journal Articles

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Neil P. Shah, MD, PhD, John M. Nicoll, BS, Eric Bleickardt, MD, Claude Nicaise, MD, Ronald L. Paquette, MD, Charles L. Sawyers, MD

Blood (2006) 108 (11): 2166.

https://doi.org/10.1182/blood.V108.11.2166.2166

Published: 2006

Journal Articles

The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy.

Neil P. Shah, MD, PhD, Brian Skaggs, PhD, Susan Branford, BS, Timothy P. Hughes, MD, John M. Nicoll, BS, Ronald L. Paquette, MD, Charles L. Sawyers, MD

Blood (2006) 108 (11): 2175.

https://doi.org/10.1182/blood.V108.11.2175.2175

Published: 2006

Journal Articles

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

Neil P. Shah, MD, PhD, John M. Nicoll, Susan Branford, Timothy P. Hughes, MD, Ronald L. Paquette, MD, Moshe Talpaz, MD, Claude Nicaise, MD, Fei Huang, Charles L. Sawyers, MD

Blood (2005) 106 (11): 1093.

https://doi.org/10.1182/blood.V106.11.1093.1093

Published: 2005

Journal Articles

Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience

Rita M. Braziel, Teresa M. Launder, Brian J. Druker, Susan B. Olson, R. Ellen Magenis, Michael J. Mauro, Charles L. Sawyers, Ronald L. Paquette, Michael E. O'Dwyer

Blood (2002) 100 (2): 435–441.

https://doi.org/10.1182/blood.V100.2.435

Published: 2002

Journal Articles

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Blood (2002) 99 (10): 3530–3539.

https://doi.org/10.1182/blood.V99.10.3530

Published: 2002

Journal Articles

Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer

Ronald L. Paquette, Sanaa T. Dergham, Ellen Karpf, He-Jing Wang, Dennis J. Slamon, Larry Souza, John A. Glaspy

Blood (2000) 96 (7): 2385–2390.

https://doi.org/10.1182/blood.V96.7.2385

Published: 2000

NARROW

Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia

Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia.

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors.

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy.

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001.

Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only